25 juny 2025
Lleida.net secures public tender in the Dominican Republic
for its electronic signature verification serviceMadrid, 23 June 2025 — Spanish technology firm Lleida.net (BME: LLN) (EPA: ALLN) (OTCQX: LLEIF) has won a public tender launched by the Dominican Institute of Telecommunications (INDOTEL) to implement its Universal Signature Verification Certificate (USVC).
This marks the company’s first USVC contract in Latin America, unlocking access to regulated sectors such as public services, land registries, and notarial systems across the Caribbean and beyond.
The USVC is a secure, API-driven verification tool that checks the authenticity, origin, and integrity of digitally signed documents. Fully compliant with the EU’s eIDAS regulation, it delivers instant, automated, and legally valid results—streamlining document workflows and ensuring legal certainty.
“In just a few years, USVC has become one of our standout products,” said Sisco Sapena, CEO of Lleida.net. “This win reinforces the strategic importance of our long-standing commitment to innovation and R&D.”
Lleida.net has been active in Latin America for over a decade, with offices in Colombia, Peru, Brazil, and the Dominican Republic. Its footprint in the region continues to expand alongside growing demand for secure digital communications.
The company posted record-breaking results in the first quarter of 2025, reporting €5.29 million in revenue—up 12% year-over-year. EBITDA soared to €1.22 million, an 84% increase, driven by disciplined cost management and successful expansion across European and Latin American markets.
Operating profit reached €716,000 for the period, representing a 387% increase compared to Q1 2024.
Founded in 1995, Lleida.net is a European leader in registered communications, electronic notifications, and digital signatures. The company holds more than 300 patents across 60+ countries in areas such as certified e-communications, e-contracting, and e-signature technologies.
Lleida.net is publicly traded on BME Growth (Madrid), Euronext Paris, OTCQX (New York), and the Stuttgart and Frankfurt stock exchanges.